Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain..
Preliminary pathological and biomarker data suggest that SARS-CoV-2 infection can damage the nervous system. To understand what, where and how damage occurs, we collected serum and CSF from patients with COVID-19 and characterized neurological syndromes involving the PNS and CNS (n = 34). We measured biomarkers of neuronal damage and neuroinflammation, and compared these with non-neurological control groups, which included patients with (n = 94) and without (n = 24) COVID-19. We detected increased concentrations of neurofilament light, a dynamic biomarker of neuronal damage, in the CSF of those with CNS inflammation (encephalitis and acute disseminated encephalomyelitis) [14 800 pg/ml (400, 32 400)], compared to those with encephalopathy [1410 pg/ml (756, 1446)], peripheral syndromes (Guillain-Barré syndrome) [740 pg/ml (507, 881)] and controls [872 pg/ml (654, 1200)]. Serum neurofilament light levels were elevated across patients hospitalized with COVID-19, irrespective of neurological manifestations. There was not the usual close correlation between CSF and serum neurofilament light, suggesting serum neurofilament light elevation in the non-neurological patients may reflect peripheral nerve damage in response to severe illness. We did not find significantly elevated levels of serum neurofilament light in community cases of COVID-19 arguing against significant neurological damage. Glial fibrillary acidic protein, a marker of astrocytic activation, was not elevated in the CSF or serum of any group, suggesting astrocytic activation is not a major mediator of neuronal damage in COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Brain communications - 3(2021), 3 vom: 11., Seite fcab099 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 16.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/braincomms/fcab099 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329398288 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329398288 | ||
| 003 | DE-627 | ||
| 005 | 20240216232145.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/braincomms/fcab099 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1295.xml |
| 035 | |a (DE-627)NLM329398288 | ||
| 035 | |a (NLM)34396099 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Paterson, Ross W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. | ||
| 520 | |a Preliminary pathological and biomarker data suggest that SARS-CoV-2 infection can damage the nervous system. To understand what, where and how damage occurs, we collected serum and CSF from patients with COVID-19 and characterized neurological syndromes involving the PNS and CNS (n = 34). We measured biomarkers of neuronal damage and neuroinflammation, and compared these with non-neurological control groups, which included patients with (n = 94) and without (n = 24) COVID-19. We detected increased concentrations of neurofilament light, a dynamic biomarker of neuronal damage, in the CSF of those with CNS inflammation (encephalitis and acute disseminated encephalomyelitis) [14 800 pg/ml (400, 32 400)], compared to those with encephalopathy [1410 pg/ml (756, 1446)], peripheral syndromes (Guillain-Barré syndrome) [740 pg/ml (507, 881)] and controls [872 pg/ml (654, 1200)]. Serum neurofilament light levels were elevated across patients hospitalized with COVID-19, irrespective of neurological manifestations. There was not the usual close correlation between CSF and serum neurofilament light, suggesting serum neurofilament light elevation in the non-neurological patients may reflect peripheral nerve damage in response to severe illness. We did not find significantly elevated levels of serum neurofilament light in community cases of COVID-19 arguing against significant neurological damage. Glial fibrillary acidic protein, a marker of astrocytic activation, was not elevated in the CSF or serum of any group, suggesting astrocytic activation is not a major mediator of neuronal damage in COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ADEM | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a NfL | |
| 650 | 4 | |a encephalitis | |
| 700 | 1 | |a Benjamin, Laura A |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Puja R |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Rachel L |e verfasserin |4 aut | |
| 700 | 1 | |a Athauda, Dilan |e verfasserin |4 aut | |
| 700 | 1 | |a Ashton, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Leckey, Claire A |e verfasserin |4 aut | |
| 700 | 1 | |a Ziff, Oliver J |e verfasserin |4 aut | |
| 700 | 1 | |a Heaney, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Heslegrave, Amanda J |e verfasserin |4 aut | |
| 700 | 1 | |a Benedet, Andrea L |e verfasserin |4 aut | |
| 700 | 1 | |a Blennow, Kaj |e verfasserin |4 aut | |
| 700 | 1 | |a Checkley, Anna M |e verfasserin |4 aut | |
| 700 | 1 | |a Houlihan, Catherine F |e verfasserin |4 aut | |
| 700 | 1 | |a Mummery, Catherine J |e verfasserin |4 aut | |
| 700 | 1 | |a Lunn, Michael P |e verfasserin |4 aut | |
| 700 | 1 | |a Manji, Hadi |e verfasserin |4 aut | |
| 700 | 1 | |a Zandi, Michael S |e verfasserin |4 aut | |
| 700 | 1 | |a Keddie, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Chou, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Vinayan Changaradil, Deepthi |e verfasserin |4 aut | |
| 700 | 1 | |a Solomon, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Keshavan, Ashvini |e verfasserin |4 aut | |
| 700 | 1 | |a Barker, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Jäger, Hans Rolf |e verfasserin |4 aut | |
| 700 | 1 | |a Carletti, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Simister, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Werring, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Spyer, Moira J |e verfasserin |4 aut | |
| 700 | 1 | |a Nastouli, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Gauthier, Serge |e verfasserin |4 aut | |
| 700 | 1 | |a Rosa-Neto, Pedro |e verfasserin |4 aut | |
| 700 | 0 | |a UCLH Queen Square COVID-19 Biomarker Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Zetterberg, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Schott, Jonathan M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain communications |d 2019 |g 3(2021), 3 vom: 11., Seite fcab099 |w (DE-627)NLM302151036 |x 2632-1297 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2021 |g number:3 |g day:11 |g pages:fcab099 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/braincomms/fcab099 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2021 |e 3 |b 11 |h fcab099 | ||